2
NEW DIMENSION ! NOVEL INSIGHTS IMMUNOTHERAPY Assessing tumor immune response with AIM chips ex vivo ORGANOTYPIC TUMOR MODELS FOR IMMUNE BLOCKADE STUDIES 1 1.Jenkins, RW., et al., Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov 2018; 8(2): 196-215. 3 POWERFUL TOOL FOR DRUG DISCOVERY MDOTS cultured in AIM chips predict the effectiveness of novel combination therapies (PD-L1 blockade + TBK1 inhibitor), as evidenced by in vivo tests using CT26 mice Cmpd 1 : TBK1 Inhibitor PRESERVES IMMUNE CELLS & TUMOR MICROENVIRONMENT RECAPITULATES THE IN VIVO IMMUNE RESPONSE SPEEDS UP DRUG DISCOVERY & DIAGNOSTICS Workflow to develop murine-derived /patient-derived organotypic tumor spheroids (MDOTS/PDOTS) in AIM chips VALIDATED AGAINST ANIMAL MODELS MDOTS cultured in AIM chips capture the in vivo responses of PD-1 sensitive MC38 and PD-1 resistant B16F10 under PD-1 treatment PD-1 Sensitive PD-1 Resistant 2 Tumor Biopsies AIM 3D Cell Culture Chips PD -1 Blockade • Dissociation • Size Selection • Immunophenotyping Downstream Analysis • Live Cell Imaging • Immunofluorescence • Proteomic Profiling • Genomic Profiling • Flow Cytometry
